Raltegravir for postexposure prophylaxis following occupational exposure to HIV

AIDS

Volumn 22, Issue 18, 2008, Pages 2552-2553

  Siegel, Marc O ^a,b   Kan, Virginia L ^a   Benator, Debra A ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PROTEINASE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE;

BILIRUBIN BLOOD LEVEL; CASE REPORT; CENTRAL VENOUS CATHETERIZATION; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LETTER; NAUSEA; NEEDLESTICK INJURY; OCCUPATIONAL ACCIDENT; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH SERVICE; PHENOTYPE; POSTEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; MALE; OCCUPATIONAL EXPOSURE; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 57349102897     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328318f184     Document Type: Letter

References (5)

1. Panlilo A, Cardo D, Grohskopt L, Heneine W, Ross C. Updated U. S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005; 54 (No. RR-9): 1-17.
2. Notice to Readers: Updated information regarding antiretroviral agents used as HIV postexposure prophylaxis for occupational HIV exposures. MMWR 2007; 56:1291-1292.
3. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
4. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 2008; 105:4832-4837.
5. US Department of Health and Human Services. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures: worldwide, 1997-2000. MMWR 2001, 49:1153-1156.